CBIO.O (CBIO.O) News
Follow CBIO.O (CBIO.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Crescent Biopharma — Potential To Initiate First CR — 001 Phase 3 Study In Early 2028
Oct 15 (Reuters) — Crescent Biopharma, Inc.: Crescent Biopharma - Potential To Initiate First Cr-001 Phase 3 Study In Early 2028 Crescent Biopharma - Multiple Sac-tmt Plus Cr-001 Phase 2 Studies Ongoing In Over 700 Patie
GEOPOLITICS | Oct 15, 2026, 09:08 PM UTC
L
Crescent Biopharma Gets FDA Clearance to Begin CR — 002 Trial
Crescent Biopharma received FDA clearance in October 2026 to begin clinical testing of CR-002, a PD-L1-targeting antibody-drug conjugate. The global Phase 1/2 APOLLO trial is scheduled to begin in fourth-quarter 2026, wi
REGULATION | Oct 15, 2026, 08:27 PM UTC